Treatment of systemic lupus erythematosus;Traitement du lupus érythémateux systémique

Revue du Praticien

Volumn 48, Issue 6, 1998, Pages 643-647

  Plette, Jean Charles ^a  

^a Service de Medecine Interne   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

CONTRACEPTION; FEMALE; HUMAN; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ANTICOAGULANT THERAPY; ARTICLE; IMMUNOSUPPRESSIVE TREATMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; THROMBOSIS;

ADRENAL CORTEX HORMONES; CONTRACEPTION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 0032520971     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Meyer O, Kahn MF. Lupus érythémateux systémique. In: Kahn MF, Pettier A, Meyer O, Rette JC (eds). Maladies et syndromes sustémiques. Paris : Flammarion MédecineSciences, 1998 (sous presse).
2. Boumpas DT, Austin HA III, Fessier Bj, BalowJE, Klippel JH, Lockshin MD. Systemic lupus erythematosus : emerging concepts. Part I : renal, neuropsychiatrie, cardiovascular, pulmonary, and hématologie disease. Ann Intern Med 1995 ; 122 : 940-50.
3. Boumpas DT, Fessier BJ, Austin HA III, BalowJE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part 2 : dermatologie and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 1995; 123: 42-53.
4. The Canadian hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N EnglJMed 1991; 324: 150-4.
5. Pétri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996; 25: 191-3.
6. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991 ; 34: 945-50.
7. Boumpas DT, Austin HA III, Vaughn EM et al. Controlled trial of pulse methylprenisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992 ; 340: 741-5.
8. Berden JHM. Lupus nephritis. Kidney Int I997;52:538-S8.
9. Caccavo D, Lagana B, Mitterhofer AP et al. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum 1997:40:27-35.
10. Rahman P, Humphrey-Murto S, Gladman DD, Urowitz MB. Cytotoxic therapy in systemic lupus erythematosus. Experience from a single center. Medicine (Baltimore) 1997:76:432-7.
11. Lewis EJ, Hunsicker LG, Lan SP et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 1992:326: 1373-9.
12. Euler HH, Schroeder JO, Harten P, Zeuner RA, Gutschmidt HJ. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 1994; 37: 1784-94.
13. Schroeder JO, Zeuner RA, Euler HH, Loffler H. High dose intravenous immunoglobulins in systemic lupus erythematosus : clinical and serological results of a pilot study. J Rheumatol 1996; 23: 71-5.
14. Drenkard C, Villa AR, Garcia-Padilla C, Perez-Vazquez ME, Alarcon-Segovia D. Remission of systemic lupus erythematosus. Medicine (Baltimore) 1996; 75: 88-98.
15. Neuwelt CM, Lacks S, Kaye BR, Ellman JB, Borenstein DG. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatrie systemic lupus erythematosus. Am J Med 1995; 98: 32-41.
16. Bootsma H, Spronk P, Derksen R et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345: 1595-9.
17. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl JMed 1995; 332: 993-7.
18. Piette JC, Wechsler B. Syndrome des antiphospholipides : un traitement mieux codifié. Presse Med 1997; 26: 108-9.
19. DU Le Thi Huong, Wechsler B, Vauthier-Brouzes D et al. Outcome of planned pregnancies in systemic lupus erythematosus. A prospective study on 62 pregnancies. Br J Rheumatol 1997; 36: 772-7.
20. Chabbert-Buffet N, Bletry O, Clauvel JP et al. Pregnane progestin is a safe contraception in patients with systemic lupus erythematosus. Arthritis Rheum 1997 ; 40 (suppl) : S 325 (abstract).
21. Sanchez-Guerrero J, Liang MH, Karlson EW, Hunter DJ, Colditz GA. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 1995; 122: 430-3.
22. Hahn BH. Animal models of systemic lupus erythematosus. In : Wallace DJ, Hahn BH (eds). Dubois lupus erythematosus, 5th edition. Baltimore : Williams & Wilkins, 1997:339-80.
23. Kalechman Y, Gafter U, Da JP, Albeck M, Alarcon-Segovia D, Sredni B. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS 101 : association with IL10 inhibition and increase in TNF-alpha levels. J Immunol 1997; 159: 2658-67.